https://scholars.lib.ntu.edu.tw/handle/123456789/631513
標題: | Regulation of dendritic cell maturation in osimertinib-treated lung adenocarcinoma patients | 作者: | Wu, Ming-Fang Chang, Ya-Hsuan Chen, Hsuan-Yu CHAO-CHI HO HUEI-WEN CHEN |
關鍵字: | CD40; CD83; Dendritic cells; Lung adenocarcinoma; Osimertinib | 公開日期: | 9-五月-2023 | 出版社: | Elsevier B.V. | 卷: | 122 | 期: | 9 | 起(迄)頁: | 955-960 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Osimertinib (OSI), a third-generation tyrosine kinase inhibitor (TKI), efficiently benefits lung adenocarcinoma (LUAD) patients with epidermal growth factor receptor (EGFR) mutations. However, combined OSI and immune checkpoint inhibitor in EGFR-mutant patients increases the incidence of interstitial lung disease (ILD), although the mechanism is unknown. Here, we investigated the interaction between dendritic cells (DCs), a potential critical player in ILD, and OSI. Seventeen LUAD patients received TKI therapy, and only the OSI therapy group (N = 10) showed a significant increase in CD40 and CD83 on immature DCs (iDCs), and an elevated trend for both markers on mature DCs (mDCs) during short- and long-term OSI therapy. Our results indicated that OSI therapy may potentially activate DC functions, which might increase the potential immune toxicity when combined with onco-immunotherapy. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/631513 | ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2023.04.018 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。